🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are actively enrolling patients with high risk bladder cancer on a trial evaluating a personalized mRNA neoantigen vaccine, autogene cevumeran, with immunotherapy following bladder surgery. Memorial Sloan Kettering Cancer Center #bladdercancer clinicaltrials.gov/study/NCT06534… mskcc.org/cancer-care/cl…

We are thrilled to announce the Hematology/Oncology fellows who will be joining MSK in July 2025! We can't wait to welcome these talented trainees. Memorial Sloan Kettering Cancer Center #Match2024

A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in Cell. With Mark Zucker, Maria Perry, and Chai Bandlamudi cell.com/cell/fulltext/…

Thrilled to share our recent work in Cell ✨ We study the extent to which tumor suppressor genes in cancer adhere to Knudson's ‘two-hit’ hypothesis, and their clinical implications. 🧵👇 Also a detailed 🧵 by Ed Reznik below: MSK Department of Pathology & Laboratory Medicine Memorial Sloan Kettering Cancer Center

🌟 What an incredible session at Keystone Symposia's Precision Oncology: Emerging Technologies & Implementation in Breckenridge, CO! ⭐️Truly honored to chair the session and introduce the phenomenal David B. Solit, MD sharing his amazing work Memorial Sloan Kettering Cancer Center #KSPrecisionOnc25

⭐️The Keystone Precision Oncology meeting was incredible! 🤩 ⭐️Attendees from academia/industry/ pharma/basic science/translational scientists/clinical trialists/ societies/ journal editors had amazing discussions. ⭐️Many of the drugs & advancements discussed with new mechanisms

The MSK GU Service recently celebrated the illustrious career of Dr. Dean Bajorin. We will miss his wisdom, insight, humor, mentorship, and leadership, but look forward to his continued input as an Emeritus Member at MSK (w/guest star Dr. Bosl).

SUPER BOWL CHAMPIONS! THIS ONE’S FOR YOU PHILLY!

🚨 Hot off the press! 🚨 The ESMO - Eur. Oncology Precision Oncology Working Group, led by the amazing Ben Westphalen G Curigliano MD PhD has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology

The Center, which builds on work conducted through a previous Endeavor Award, will be led by co-principal investigators Cory Abate-Shen, Anil K. Rustgi, & Michael Shen of @ColumbiaCancer Columbia Medicine and David B. Solit, MD of Memorial Sloan Kettering Cancer Center. #CancerResearch

I just heard huge news that needs to be celebrated! Today marks 40 years of research and care for Dr Mark Kris Memorial Sloan Kettering Cancer Center Dr Kris has been a champion for innovative research, playing a pivotal role in many advancements over the past 4 decades. His contributions to science

Congratulations to the MSK-IMPACT team at MSK for receiving the American Association for Cancer Research (AACR) Team Science Award. The team, led by Michael Berger, David B. Solit, MD, and Marc Ladanyi, is recognized for its pivotal advances in clinical genomic sequencing that have transformed

.Michael Berger, David B. Solit, MD, Marc Ladanyi, and the MSK-Impact team accept the AACR Team Science Award for developing and implementing a groundbreaking next-generation sequencing platform which has enabled the comprehensive molecular characterization of over 125,000 tumors. #AACR25

‼️Divergent histology in bladder cancer impacts outcomes and genomics. ‼️In 3052 RC patients, UCAH subtypes (plasmacytoid, micropapillary, sarcomatoid) showed worse survival. 🎯Genomic targets: ERBB2 (micropapillary), FGFR3 (nested/squamous), PTEN (sarcomatoid).

Poster sessions at #AACR25 are underway! Moriah Heller Nissan, PhD and Sarah Phillips Suehnholz shared updates on OncoKB™, MSK’s precision oncology knowledge base. In 2024, 17 new biomarkers and 26 therapies were added, further advancing targeted #cancer care. 🧬 AACR

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma sciencedirect.com/science/articl… This study examined the clinical outcomes & genomic landscape of urothelial carcinoma with aberrant histology (UCAH) in a cohort

Had a successful #AACR25 with the Solit team. Congrats again to David Solit, Michael Berger, and everyone at MSK IMPACT for winning the Team Science Award.

Excited to see our paper in print European Urology: europeanurology.com/article/S0302-… Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma

The greatest of honors to give the Whitmore Lecture. Thank you Society of Urologic Oncology #AUA2025 Forever indebted to the 3 inspirational bosses/role models that I've been so fortunate to have worked with over my career: Donald G. Skinner, Peter T. Scardino and James A Eastham Memorial Sloan Kettering Cancer Center